caa a22 4500 477057322 CHVBK 20180405111350.0 cr unu---uuuuu 170330e19960601xx s 000 0 eng 10.1007/s002280050104 doi (NATIONALLICENCE)springer-10.1007/s002280050104 Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor, compared to hydrochlorothiazide in elderly patients [Elektronische Daten] [B. Persson, M. Stimpel] Objective: To compare the antihypertensive efficacy of moexipril, a new angiotensin-converting enzyme (ACE) inhibitor, to treatment with hydrochlorothiazide (HCTZ). Patients: Two hundred and one non-hospitalized male and female patients between 65 and 80 years of age with essential hypertension. Methods: This was a multicentre, placebo-controlled, double-blind study with a parallel group design. Subjects with a sitting diastolic blood pressure (DBP) ≥ 95 mmHg were randomized to monotherapy with placebo, moexipril 7.5 mg o.d., moexipril 15 mg o.d. or HCTZ 25 mg o.d. for 8 weeks. Results: Throughout the study period treatment with moexipril and HCTZ resulted in significant reductions of DBP compared with placebo, but there were no significant differences between the active treatment groups. At end point the adjusted mean reductions were 10.5, 8.7 and 10.1 mmHg in the HCTZ, moexipril 7.5 mg and moexipril 15 mg groups, respectively, compared to 3.9 mmHg in the placebo group. Treatment with moexipril was associated with two cases of first dose hypotension and two cases of moderate and reversible increases in serum creatinine levels. Otherwise, both dosages of moexipril were well tolerated and the overall percentages of patients who had adverse experiences were smaller than in the placebo group. Conclusion: Moexipril is well tolerated and is at least as effective as HCTZ in elderly patients with essential hypertension. Springer-Verlag Berlin Heidelberg, 1996 Key words Moexipril nationallicence Hypertension nationallicence Hydrochloro-thiazide nationallicence elderly patients nationallicence Persson B. Department of Medicine, Sahlgren's Hospital, S-413 45 Gothenburg, Sweden, SE aut Stimpel M. Department of Clinical Research, Schwarz Pharma AG, D-40789 Monheim, Germany, DE aut https://doi.org/10.1007/s002280050104 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s002280050104 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Persson B. Department of Medicine, Sahlgren's Hospital, S-413 45 Gothenburg, Sweden, SE aut NATIONALLICENCE 700 1- Stimpel M. Department of Clinical Research, Schwarz Pharma AG, D-40789 Monheim, Germany, DE aut Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer